List view / Grid view
19 May 2015 | By Victoria White
Regeneron and Sanofi have shared positive results from an interim analysis of a pivotal Phase 2b study of dupilumab in adult patients with moderate to-severe asthma, who are uncontrolled despite treatment with inhaled corticosteroids and long-acting beta agonists (ICS/LABA).
19 May 2015 | By Victoria White
Clinical experience of biosimilar infliximab shows that the treatment is comparable to the reference medicinal product in terms of efficacy and safety...
18 May 2015 | By Victoria White
CPhI Worldwide has announced its Expert Panel for CPhI Worldwide 2015 ahead of the eagerly anticipated annual report (3rd edition)...
18 May 2015 | By Victoria White
The first patient has been dosed in the Phase 2 clinical trial of tipifarnib in patients with locally advanced tumours that carry HRAS mutations...
18 May 2015 | By Victoria White
The FDA has granted Fast Track designations to luspatercept for two separate indications for the treatment of patients with beta-thalassemia...
18 May 2015 | By
Endo is set to acquire privately-held Par Pharmaceutical in a transaction valued at $8.05 billion. The acquisition will expand Endo's generics business...
18 May 2015 | By Victoria White
Data from two Phase 3 studies of Orkambi, an investigational medicine designed to treat the underlying cause of cystic fibrosis, have been published...
18 May 2015 | By Victoria White
Boehringer Ingelheim has acquired Pharmaxis’ investigational drug PXS4728A, to develop it for the treatment of NASH and to prevent its consequences...
18 May 2015 | By Victoria White
Amgen has announced the first results from its global Phase 2 study evaluating the efficacy and safety of AMG 334 for the prevention of episodic migraine...
The US Food and Drug Administration (FDA) has granted Abbvie’s Humira® (adalimumab) Orphan Drug Designation for the investigational treatment of moderate-to-severe hidradenitis suppurativa (Hurley Stage II and Hurley Stage III disease), a painful, chronic inflammatory skin disease.
15 May 2015 | By Victoria White
SAGE-547 demonstrated robust activity, with a 77% response rate in patients with SRSE, in a successfully completed Phase 1/2 clinical trial...
15 May 2015 | By Victoria White
AcelRx Pharmaceuticals has entered into a contract to develop ARX-04 worth up to $17.0 million, supported by the US Department of Defence (DoD)...
15 May 2015 | By Victoria White
Takeda has decided to discontinue the Phase 3 trial of alisertib (MLN8237) for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)...
14 May 2015 | By Victoria White
Teva will present further data from its chronic migraine Phase IIb study of TEV-48125 at the 17th Congress of the International Headache Society on Friday...
14 May 2015 | By Victoria White
Roche has announced interim results from a global, randomised Phase II study (POPLAR) of MPDL3280A in people with previously treated NSCLC...
